Relation between cathepsin D expression and other prognostic factors in breast carcinomas

Shaheen, Raymond M.; Miseljic, Slobodan; Wiehle, Ronald D.; Wittliff, James L.

doi:10.1093/clinchem/41.11.1585

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between p185 status and that of Cat D is still controversial. While diverse authors have found a positive association between both variables (Tetu and Brisson, 1994;Eng Tan et al, 1994), others could find no relationship (Isola et al, 1993;Marsigliante et al, 1993;Shaheen et al, 1995). Using quantitative data, we have shown that both parameters are positively correlated (in fact, this was the best correlation obtained in the whole tumor series), and that tumors considered as p185-positive were more frequently positive for Cat D than tumors considered as p185negative.…”

Section: Discussionmentioning

confidence: 48%

“…The HER-2/neu gene status has also been studied in conjunction with other biological prognostic markers, especially with estrogen (ER) and progesterone (PR) receptors, and to a lesser extent with cathepsin D (Cat D) and pS2. While most studies have shown a significant association between p185 overexpression and steroid-receptor negativity (Tandon et al, 1989;Kallioniemi et al, 1991;Ciocca et al, 1992), its relationship with Cat D and pS2 is still controversial (Isola et al, 1993;Tetu and Brisson, 1994;An et al, 1995;Shaheen et al, 1995).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Quantitative analysis of p185HER-2/neu protein in breast cancer and its association with other prognostic factors

et al. 1997

View full text Add to dashboard Cite

The total cellular p185 HER-2/neu protein (p185) content was measured by ELISA in 346 invasive primary breast cancers, and the results were compared with those of estrogen (ER) and progesterone (PR) receptors, pS2 and Cathepsin D (Cat D) content. At a cut-off level of 260 fmol/mg protein, 53 of the 346 tumors (15%) were p185-positive. A significant positive correlation was observed between p185 levels and those of Cat D, and a weaker, though significant, positive correlation with ER, and pS2 levels, but not with those of PR. However, when only the 293 p185-negative tumors were considered, the correlation between p185 and ER improved substantially, and statistical significance was reached for PR. p185-positive tumors exhibited lower ER and PR content and higher Cat D content than p185-negative tumors. The pS2 content, in contrast, did not undergo significant variation. Tumors considered to be p185-positive were significantly more frequently positive for Cat D at the cut-off of 45 pmol/mg protein, and were more frequently negative for ER and/or PR, but only significant at the cut-off of 15 fmol/mg or higher for both steroid receptors. Finally, p185 status was not associated with menopausal status, tumor size, axillary-lymph-node invasiveness or distant metastases. These results suggest that 260 fmol/mg protein as the cut-off for p185 allows the identification of a tumoral sub-population with a more aggresive phenotype. Int.

show abstract

Section: Discussionmentioning

confidence: 48%

mentioning

confidence: 99%

Quantitative analysis of p185HER-2/neu protein in breast cancer and its association with other prognostic factors

et al. 1997

View full text Add to dashboard Cite

show abstract

“…The specific binding capacity of EGFR (36) and levels of Cath‐D (37) and c‐erbB‐2 oncoprotein (38) were determined as described earlier.…”

Section: Methodsmentioning

confidence: 99%

Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer

Tecimer¹,

Doering²,

Goldsmith³

et al. 2000

Int J Gynecol Cancer

View full text Add to dashboard Cite

Urokinase-type plasminogen activator (uPA), its receptor (uPAR) and inhibitor, plasminogen activator-type 1 (PAI-1) are proposed to be of prognostic significance in some cancers. To determine the prognostic value of the urokinase plasminogen activation system in ovarian cancer, levels of uPA, uPAR, and PAI-1 were measured in extracts of ovarian cancer tissue using ELISA tests. uPA and PAI-1 were determined in 70 tumor extracts and uPAR in 43 extracts. Levels were correlated with age, tumor histology, stage, grade, lymph node and metastatic status, residual disease, risk of recurrence, epidermal growth factor receptor (EGFR) expression, cathepsin D (Cath-D), and c-erbB-2 levels. uPA and uPAR did not exhibit correlation with any of these parameters. However, patients with high grade tumor, recurrence, and lower EGFR and Cath-D had significantly higher PAI-1 levels compared to those of others (P < 0.05). Kaplan-Meier plots of survival were compared. uPA and uPAR were not related to disease-free or overall survival. Although low PAI-1 appeared to predict a longer overall survival, the difference was not statistically significant. Multivariate analysis revealed that PAI-1 was a predictor for overall survival although it was not as strong as stage. These results suggest that elevated PAI-1 seems to be correlated with an unfavorable prognosis in ovarian cancer.

show abstract

“…Reference specimens for the sex-steroid receptors (28) and cathepsin D (29) have been developed earlier as a part of the responsibility of the Hormone Receptor Laboratory as a national reference facility. Specific reference samples made of pooled human tissues containing known quantities of uPA or PAI-1 were produced for this study.…”

Section: Quality Controlmentioning

confidence: 99%

Expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor in colon disease

Miseljic

Galandiuk

Myers

et al. 1995

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Surveillance colonoscopy and biopsy are inaccurate methods of predicting the likelihood of ulcerative colitis patients to develop colon carcinoma. We examined uPA and PAI-1 as potential markers for assessing these patients and those with familial polyposis who are at risk of developing colon cancer. For comparison, biopsies of normal colon and Crohn's disease were evaluated. We examined 77 colonic mucosa specimens taken from patients undergoing elective resection for benign and malignant colonic disease. uPA and PAI-1 were measured using a monoclonal antibody-based ELISA kit (American Diagnostica, Greenwich, CT) and expressed as ng/mg extract protein. Intra- and interassay controls of uPA gave CV = 3-4% and CV = 8-9%, respectively, while those for PAI-1 were 6-7% and 10-11%, respectively. The Mann-Whitney test showed that both uPA and PAI-1 expression were significantly higher in colon cancer, chronic ulcerative colitis, and Crohn's disease than in normal colon. uPA in familial polyposis samples was similar to that of normal colon, while PAI-1 was much lower than in normal colon. Neither patient age nor sex appeared to influence the expression of these potential markers in any tissue. The pattern of uPA and PAI-1 expression in normal, benign and malignant colon suggests these proteins deserve further consideration as markers for assessing colon carcinoma risk.

show abstract

Relation between cathepsin D expression and other prognostic factors in breast carcinomas

Cited by 6 publications

References 19 publications

Quantitative analysis of p185HER-2/neu protein in breast cancer and its association with other prognostic factors

Quantitative analysis of p185HER-2/neu protein in breast cancer and its association with other prognostic factors

Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer

Expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor in colon disease

Contact Info

Product

Resources

About